Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adults

Intranasally applied insulin is one of the antigen‐specific therapies currently tested in clinical type 1 diabetes prevention trials, for example, in the Type 1 Diabetes Prediction and Prevention Study (DIPP). The possibility that the therapy may cause hypoglycaemia or local irritation and the poorly known immunological safety of mucosal application of the antigen in healthy subjects prompted this study.

[1]  S. Madsbad,et al.  Intranasal insulin therapy: the clinical realities , 1995, Diabetologia.

[2]  I. Macdonald,et al.  Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia , 1992, Diabetologia.

[3]  J. Bach,et al.  Immunotherapy of insulin-dependent diabetes mellitus. , 2001, Current opinion in immunology.

[4]  A. Cooke,et al.  Tolerogenic strategies to halt or prevent type 1 diabetes , 2001, Nature Immunology.

[5]  A. Hämäläinen,et al.  Pregnancy induces nonimmunoglobulin insulin‐binding activity in both maternal and cord blood serum , 2001, Clinical and experimental immunology.

[6]  A. Hämäläinen,et al.  Feasibility of genetic and immunological prediction of Type I diabetes in a population-based birth cohort , 2001, Diabetologia.

[7]  C. Boitard,et al.  Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial , 2000, The Lancet.

[8]  E. Bonifacio,et al.  Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens. , 2000, Diabetes.

[9]  A. Rosenbloom.  Prevention of Type 1 Diabetes: Perspectives , 2000 .

[10]  J. Krischer,et al.  Therapeutic controversy: prevention and treatment of diabetes in children. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  J. Ilonen,et al.  Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children , 1998, Diabetologia.

[12]  E. Bonifacio,et al.  IA-2 antibodies – a sensitive marker of IDDM with clinical onset in childhood and adolescence , 1998, Diabetologia.

[13]  P. Bingley,et al.  A novel micro-assay for insulin autoantibodies. , 1997, Journal of autoimmunity.

[14]  L. Harrison,et al.  Aerosol Insulin Induces Regulatory CD8 γδ T Cells That Prevent Murine Insulin-dependent Diabetes , 1996, The Journal of experimental medicine.

[15]  E. Rubin.  Hypoglycemic disorders. , 1995, The New England journal of medicine.

[16]  P. Laippala,et al.  Evaluation of nasal resistance data in active anterior rhinomanometry with special reference to clinical usefulness and test-retest analysis. , 1992, Clinical otolaryngology and allied sciences.

[17]  E. Bechgaard,et al.  Intranasal administration of insulin to humans. , 1991, Diabetes research and clinical practice.

[18]  J. Karjalainen,et al.  Islet Cell Antibodies as Predictive Markers for IDDM in Children With High Background Incidence of Disease , 1990, Diabetes.

[19]  M. Kenward,et al.  The analysis of data from 2 x 2 cross-over trials with baseline measurements. , 1987, Statistics in medicine.

[20]  G. Jerums,et al.  Long-Term Use of Intranasal Insulin in Insulin-Dependent Diabetic Patients , 1987, Diabetes Care.

[21]  J. Manson,et al.  Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. , 1985 .

[22]  J. Flier,et al.  Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects , 1983, Diabetes.